Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/111642
Title: The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study
Author: Gómez-Acebo, Inés
Dierssen-Sotos, Trinidad
Palazuelos, Camilo
Pérez-Gómez, Beatriz
Lope, Virginia
Tusquets, Ignasi
Alonso, M. Henar
Moreno Aguado, Víctor
Amiano, Pilar
Molina de la Torre, Antonio José
Barricarte, Aurelio
Tardón, Adonina
Camacho, Antonio
Peiró, Rosana
Marcos-Gragera, Rafael
Muñoz, Montse
Michelena-Echeveste, Maria Jesus
Ortega Valin, Luis
Guevara, Marcela
Castaño-Vinyals, Gemma
Aragonés, Nuria
Kogevinas, Manolis
Pollán, Marina
Llorca Díaz, Javier
Keywords: Càncer de mama
Hormones
Hormonoteràpia
Oncologia
Canals de calci
Breast cancer
Hormones
Hormone therapy
Oncology
Calcium channels
Issue Date: 10-Aug-2016
Publisher: Public Library of Science (PLoS)
Abstract: INTRODUCTION: The evidence on the relationship between breast cancer and different types of antihypertensive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate has recently been fueled again with new data reporting an increased risk of breast cancer among women with a long history of use of antihypertensive drugs compared with nonusers. METHODS: In this case-control study, we report the antihypertensive drugs-breast cancer relationship in 1,736 breast cancer cases and 1,895 healthy controls; results are reported stratifying by the women's characteristics (i.e., menopausal status or body mass index category) tumor characteristics and length of use of antihypertensive drugs. RESULTS: The relationship among breast cancer and use of calcium channel blockers (CCB) for 5 or more years had odds ratio (OR) = 1.77 (95% CI, 0.99 to 3.17). Stratifying by BMI, the OR increased significantly in the group with BMI ≥ 25 (OR 2.54, 95% CI, 1.24 to 5.22). CCBs were even more strongly associated with more aggressive tumors, (OR for invasive tumors = 1.96, 95% CI = 1.09 to 3.53; OR for non ductal cancers = 3.97, 95% CI = 1.73 to 9.05; OR for Erbb2+ cancer = 2.97, 95% CI: 1.20 to 7.32). On the other hand, premenopausal women were the only group in which angiotensin II receptor blockers may be associated with breast cancer (OR = 4.27, 95% CI = 1.32 to 13.84) but this could not be identified with any type or stage. Use of angiotensin-converting-enzyme inhibitors, beta blockers and diuretics were not associated with risk. CONCLUSIONS: In this large population-based study we found that long term use of calcium channel blockers is associated with some subtypes of breast cancer (and with breast cancer in overweight women).
Note: Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0159672
It is part of: PLoS One, 2016, vol. 11, num. 8, p. e0159672
Related resource: https://doi.org/10.1371/journal.pone.0159672
URI: http://hdl.handle.net/2445/111642
ISSN: 1932-6203
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
665137.pdf223.94 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons